11:46 AM EST - Prometic Life Sciences Inc. : Announced new long-term clinical data from its pivotal Phase 2/3 trial of Ryplazym™ (Plasminogen IV) in patients with congenital plasminogen deficiency. The data demonstrates that in 10 patients treated with RyplazymTM for a total of 48 weeks, there was no recurrence of lesions and no safety or tolerability issues observed related to this longer-term dosing. Prometic Life Sciences Inc.
shares T.PLI are trading down $0.03 at $1.59.
